We report the three-dimensional structure of a β-catenin armadillo repeat in complex with the liver receptor homolog-1 (LRH-1) ligand binding domain at 2.8 Å resolution as the first structure of β-catenin in complex with any nuclear receptor. The surface of β-catenin that binds LRH-1 partly overlaps defined contact sites for peptide segments of β-catenin partners, including T-cell factor-4. The surface of LRH-1 that engages β-catenin is comprised of helices 1, 9, and 10 and is distinct from known interaction surfaces of LRH-1, including corepressor and coactivator binding sites. Targeted mutagenesis of amino acids forming both sides of the LRH-1/β-catenin interface reveals that they are essential for stable interactions between these proteins in solution. The LRH-1 binding site in β-catenin is also required for association with androgen receptor, providing evidence that the observed LRH-1/β-catenin interaction may be prototypic.
We report the three-dimensional structure of a β-catenin armadillo repeat in complex with the liver receptor homolog-1 (LRH-1) ligand binding domain at 2.8 Å resolution as the first structure of β-catenin in complex with any nuclear receptor. The surface of β-catenin that binds LRH-1 partly overlaps defined contact sites for peptide segments of β-catenin partners, including T-cell factor-4. The surface of LRH-1 that engages β-catenin is comprised of helices 1, 9, and 10 and is distinct from known interaction surfaces of LRH-1, including corepressor and coactivator binding sites. Targeted mutagenesis of amino acids forming both sides of the LRH-1/β-catenin interface reveals that they are essential for stable interactions between these proteins in solution. The LRH-1 binding site in β-catenin is also required for association with androgen receptor, providing evidence that the observed LRH-1/β-catenin interaction may be prototypic.
crystal structure | crystallography | protein-protein interaction L iver receptor homolog-1 (LRH-1, NR5A2) is a member of the nuclear hormone receptor (NR) family of transcription factors with essential roles in development, metabolism, and cancer (1) . LRH-1 is critical in multiple stages in early development (2, 3) and maintenance of mouse embryonic stem (ES) cell pluripotency (3) . In this context, LRH-1 is an upstream regulator of Oct4, a transcription factor that is essential for embryonic stem cell identity (3) , and can substitute for Oct4 in generation of induced pluripotent stem cells (4) . LRH-1 is also implicated in pancreas development, differentiation, and function (5) and regulates steroid synthesis and cholesterol and bile acid homeostasis in several tissues (1, (6) (7) (8) (9) and can convert mesenchymal stem cells into steroidogenic cells (10) . Additionally, LRH-1 promotes aberrant growth in multiple cancers, including gastrointestinal tumors (11) and some breast cancers (12) . A genome-wide association study identified five of the eight highly significant SNPs for pancreatic cancer in the LRH-1 gene 5′ region (13) . A recent report showed that LRH-1 regulates pancreatic cancer cell growth and proliferation (14) .
Like other NRs, LRH-1 and its close homolog steroidogenic factor 1 [SF-1; also Ad4 binding protein (Ad4BP) or NR5A1] are multidomain proteins. LRH-1 and SF-1 are comprised of a C-terminal ligand binding domain (LBD), and an N-terminal domain linking a DNA binding domain (DBD) comprised of two zinc fingers and a Fushi tarazu-F1 motif that allows the receptor to bind to DNA as monomers (15, 16) connected by a long hinge that bridges the DBD and LBD and is the target of posttranslational modification (17) . Three-dimensional structures of human and mouse LRH-1 LBDs reveal a canonical NR fold with an extra helical element stabilizing the receptor in the absence of hormone and accounting for constitutive activity (18) (19) (20) (21) . The hLRH-1 LBD structures revealed bacterial phosphatidylglycerol and phosphatidylethanolamine in the well-formed hormone binding pocket suggesting this class of ligands are potential physiological agonists (19, 20) . In addition, Lee et al. recently reported that dilauroyl phosphatidylcholine is an LRH-1 agonist ligand in vitro (22) .
LRH-1 modulates transcription by directing transcription factor assembly at appropriate response elements on DNA. Two special NRs of the NR0B subfamily, small heterodimer partner (SHP) and dosage-sensitive sex reversal, adrenal hypoplasia critical region, on chromosome X, gene 1 (Dax-1) (23-25), act as repressors of constitutive LRH-1 activity and bind the LBD at the activation function-2 (AF-2) site where classic NR coactivators steroid receptor coactivators (SRCs) also interact (26) . LRH-1 also binds the fundamentally distinct coactivator β-catenin, which accumulates in the nucleus upon Wnt activation (27) . LRH-1/β-catenin interactions are implicated in induction of cyclin D1 and E1 and LRH-1-dependent cell proliferation (27) . SF-1 (28) (29) (30) (31) and nuclear hormone receptor (NHR) 25 (32) , the Caenorhabditis elegans SF-1 ortholog, also bind β-catenin. Moreover, unrelated NRs, including androgen receptor (AR) (33) and others (34) modulate transcription through β-catenin association. Presently, NR/β-catenin contact modes are not well understood at an atomic level.
As the principal agent of Wnt-dependent effects on cell adhesion, differentiation, and cancer, β-catenin engages in multiple protein-protein contacts (35, 36) , some of which are understood in atomic detail (37, 38) . β-catenin is comprised of a central association region, the armadillo-repeat region (ARM) (39) , and N-and C-terminal transactivation domains. Whereas the N-and C-terminal regions are intrinsically unstructured (40) , the ARM is comprised of 12 repeated three-helix structures (ARM-1 to -12), which adopt a superhelical organization. X-ray structures of the ARM have been determined with interacting fragments of TCF-4 (41, 42) , inhibitor of beta-catenin and TCF-4 (ICAT) (43) , Axin (44), B-cell chronic lymphocytic leukemia/lymphoma 9 (BCL9) (45) , and others (37, 38) . In most cases, α-helical or unstructured polypeptide segments from the partner dock into a positively charged groove formed by linked ARMs (38) . BCL9 binds the N-terminal tip of the ARM and can form a trimeric complex with β-catenin and TCF-4 (45) .
NR/β-catenin contact modes are complex, but there is evidence that NR LBDs are important for contact in some cases (34) . Although phosphorylation-dependent interactions between the retinoid orphan receptor α N-terminal domain and β-catenin are important for attenuation of Wnt/β-catenin signaling (46) , biochemical and genetic evidence reveals that LRH-1 and AR LBDs bind the ARM (27, 33, 34) , with AR exhibiting strong dependence on the ARM-5 and ARM-6 (33). β-catenin synergizes with SRC-2 to hyperactivate AR and the isolated AR LBD (47) suggesting that the β-catenin binding surface differs from AF-2 (47) .
Here, we report the crystal structure of a complex of the LRH-1 LBD and the β-catenin at 2.8 Å resolution. The LRH-1 LBD utilizes a novel interaction surface to dock into the positively charged groove at a site that partially overlaps the binding surface for TCF-4. Mutational analysis verified the observed interaction and raises the possibility that LRH-1/β-catenin interactions may be prototypic for other NRs.
Results
The LRH-1 LBD/β-Catenin Complex. We expressed, purified, and cocrystallized protein fragments corresponding to the β-catenin armadillo repeat (amino acids 138-663) and the hLRH-1 hinge LBD (amino acids 191-541) (SI Materials and Methods). Biochemical measurements suggested that the complex was specific. Crystals of the complex grew readily. The structure of the complex was solved from the P2 1 crystal form (Fig. 1 ). The final model is refined to 2.8 Å with R free ∕R work values of 24.26∕19.88. The polypeptide chains, forming the complex, were well resolved except for a loop region in ARM-10 of β-catenin and the loop between helix (H) 2 and H3, H3 and H4, and H11 and H12 in LRH-1 LBD and includes residues L148-Q548 and Q559-R661 for β-catenin and A299-A331, K338-S363, Q374-V461, and Q468-A538 for LRH-1 LBD (Fig. 1 ). The LRH-1 hinge (aa191-298), which was included in the expression vector, was invisible in the electron density map and was not included in the structure. Details of structure determination and refinement are summarized in Table S1 .
Visual inspection of both components of the complex reveals characteristic overall folds observed in prior X-ray structures (37) (38) (39) 48) . There are no significant changes in the LRH-1 LBD relative to previous hLRH-1 structures (19, 20) and the ligand binding pocket holds a phosphatidyl lipid of bacterial origin (stick representation, Fig. 1 ). However, comparisons of α-carbon positions with previous β-catenin [Protein Data Bank (PDB): 1JDH] yielded root mean squared deviations of 1.75 Å, suggesting that β-catenin undergoes significant conformational changes on binding to LRH-1. To understand the mechanisms of β-catenin conformational change, we compared β-catenin structures in complex with LRH-1 LBD (this study) and TCF-4 (1JDH). Dyn-Dom analysis (49) of LRH-1 and TCF-4 complexes identified two domains in β-catenin. Domains 1 and 2 consist of amino acid residues 150-388, 394-409, and 414-419 and 389-393, 410-413, and 420-659, respectively (Table S2 ). Rmsd of domain 1 and 2 were 1.18 Å and 0.7 Å, respectively. An angle relating the principal axes of these two was also defined (49) . The rotation angle is 12.1°, translation is −0.1 Å, and the closure is 24.4%. The analysis also identified amino acid residues 388-396, 409-414, and 419-420 (these residues are in ARM-6 and -7) as the hinge region for the conformational change. Fig. S1 shows that domain 1-or 2superposed structures of β-catenin complexed with TCF-4 (1JDH) to LRH-1/β-catenin complex. The hinge regions allowed the conformational changes of β-catenin to accommodate and bind to LRH-1. A green arrow points to a part of β-catenin in the LRH-1 complex that is closer to the partner, LRH-1, than when β-catenin binds TCF-4. Thus, β-catenin closes more with LRH-1 than TCF-4 suggesting that β-catenin has the capacity to adapt to different interacting proteins.
LRH-1/β-Catenin Interactions. The LRH-1 binding region in β-catenin overlaps that for previously defined β-catenin interacting proteins, including TCF-4, ICAT, and others, but the binding mode of the LRH-1 LBD to β-catenin is unique. Like many other β-catenin partners, the LRH-1 LBD docks into the positively charged armadillo-repeat groove. The binding site partly overlaps the main contact surface for TCF-4 ( Fig. 2) ; LRH-1 occupies a location that binds one of two TCF-4 α-helical segments that contact the groove. Analysis of ratios of buried surface area (BSA) in each ARM versus total surface area buried by LRH-1 and by TCF-4 confirms that binding surfaces only partly overlap ( Fig. S2 ). Whereas ARM-4 (aa 277-318) makes most contacts with LRH-1 and TCF-4 ( Fig. S2 ), LRH-1 contacts are mostly restricted to ARM-3 to -7 and the TCF-4 interface is more widely distributed throughout ARM-3 to -9. Unlike other β-catenin partners, LRH-1 does not utilize unstructured peptide or long α-helical segments to bind β-catenin and retains its classic NR α-helical sandwich configuration.
LRH-1 engages β-catenin quite differently from other coregulators such as peroxisome proliferator-activated receptor gamma coactivator 1-apha, SRC-2, and Dax-1. The LBD surface that binds β-catenin has never previously been implicated in cofactor contact; it is comprised of predominantly polar surface exposed residues from H1, H9, H10, and the intervening loop between the latter helices ( Fig. S3) . The surface appears well conserved in LRH-1 sequences from other species and mostly conserved in SF-1 (Fig. S4) . The LRH-1 contact surface with β-catenin is larger than AF-2; calculated BSA for the LRH-1/β-catenin complex is 1;591 Å 2 compared to 1;162 Å 2 for the LRH-1/SRC-2 NR box 3 peptide (50) (Figs. S3 and S5, Left). Moreover, it is widely separated from AF-2, by 30-40 Å and is on the opposite side of the LBD from H7-H11, which contacts one component of the Dax-1 dimer in a heterotrimeric LRH-1/ðDax-1Þ 2 complex (25) (Fig. S5,  Right) . Thus, LRH-1 could retain the capacity to bind other coregulators when assembled with β-catenin.
We analyzed specific amino acids involved in LRH-1/β-catenin contacts. The interface is formed by 29 side chains from β-catenin and 28 side chains from LRH-1. β-catenin Y306 presents the largest interface (128 Å 2 BSA) for LRH-1 and forms hydrogen bonds with LRH-1 S300, D483, and N488 side chains ( Fig. 3  A and B) . The β-catenin W383 indole ring presents additional 98 Å 2 BSA, forming a hydrogen bond with LRH-1 P490. β-catenin residues K312 and R386 make hydrogen bonds with LRH-1 Fig. 1 . Structure of the LRH-1/β-catenin complex. β-catenin is represented in green, and hLRH-1 is in cyan. The ligand of the LRH-1 is in blue (ball and stick). D483 and T493, respectively. Although many β-catenin amino acids that bind LRH-1 are also implicated in contacts with TCF-4 and other proteins, there are clear differences in their binding modes. For example, β-catenin W383 contacts LRH-1 but not TCF-4 (PDB: 1JDH); another key interface residue of β-catenin, K345, presents 49 Å 2 BSA for LRH-1 compared to only 25 Å 2 BSA for TCF-4. On the LRH-1 surface, M486 also has significant contact with β-catenin, 106 Å 2 BSA, and forms a hydrogen bond with N387.
Mutational Analysis of the LRH-1/β-Catenin Interface. To verify the observed protein-protein interactions, we examined the effects of mutations on either side of the interface using solution GSTpulldown and competing peptide binding assays. Mutation of key β-catenin amino acids Y306, K345, and W383 or LRH-1 residues D483, M486, and T493 to Ala inhibited formation of the LRH-1/β-catenin complex ( Fig. 4 A and B) . In addition, a TCF-4 peptide inhibited LRH-1 binding to their partially overlapping site on the β-catenin surface, whereas a BCL9 peptide, which binds at a distinct location, had no effect (Fig. 4C) .
Effects of β-catenin and LRH-1 mutations were also analyzed in transfection assays that utilized expression vectors for a fusion protein composed of the yeast GAL4 DNA binding domain and the LRH-1 LBD, β-catenin, and a GAL4 responsive reporter in cultured CV-1 cells. As previously shown by Botrugno et al. (27) we found that β-catenin is a relatively weak LRH-1 coactivator, yielding twofold potentiation of reporter activity in the presence of GAL-LRH-1 at low doses (10 ng) of transfected β-catenin vector (Fig. 5A) , and auto-inhibition of LRH-1 activity at higher doses. Key β-catenin mutations Y306A and W383A blocked the ability of β-catenin to coactivate GAL-LRH-1 (Fig. 5A) . Similar effects were not seen at a TCF-4 responsive reporter, where the βcatenin Y306A and K345A mutants exhibited partially reduced coactivation relative to wild-type β-catenin ( Fig. 5B ) and W383A mutant showed partially enhanced coactivation. This finding implies that β-catenin contact surfaces for LRH-1 are overlapping, but nonidentical, and that β-catenin mutants that fail to coactivate LRH-1 (Y306A and W383A) are expressed in functional form. Likewise, LRH-1 point mutations that affect the β-catenin binding interface (D483A, M486A) reduced transcriptional activity of the GAL-LRH-1 LBD fusion and blocked its capacity for coactivation by β-catenin ( Fig. 5C ).
Might these points of contact play a role in associations with other NRs? β-catenin mutations that inhibit binding to LRH-1 also block interactions of β-catenin with AR. β-catenin is an effective coactivator of a GAL-AR LBD fusion protein in the presence of hormone (dihydrotestosterone, DHT). This activating effect was reduced by mutating key β-catenin residues that participate in LRH-1 binding (Fig. 6A) . Likewise, the same mutations inhibited β-catenin interactions with a bacterially expressed AR LBD-DHT complex in GST-pulldown assays (Fig. 6B ). Complementing these data, the TCF-4 peptide, but not the BCL9 peptide, inhibited AR/β-catenin binding interactions ( Fig. 6C ). Finally, our bacterially expressed LRH-1 LBD preparations competed for AR binding to GST-β-catenin ( Fig. S6A ). Based on these results, we hypothesize that the observed LRH-1 interactions with β-catenin may be prototypic for AR LBD, and possibly other NR LBDs.
Discussion
The LRH-1/β-Catenin Interface. The structure of a complex of a NR with β-catenin reveals surprising analogies between interaction modes of the LRH-1 LBD and other β-catenin partners. Whereas the α-helical globular organization of the LRH-1 LBD and its molecular surface differs greatly from the contact surfaces of other β-catenin partners, which present as unstructured peptides or short α-helices linked by coiled regions (37, 38) , LRH-1 nevertheless docks into the charged groove formed by the β-catenin armadillo repeats at a position that overlaps previously defined binding sites for TCF-4 and other partners. In support of the validity of the observed interaction, targeted β-catenin mutations and a TCF-4 peptide disrupt LRH-1/β-catenin complex formation in solution, whereas a BCL9 peptide, previously shown to bind to β-catenin at a distinct location from TCF-4, does not. A clear example of induced fit, the structure shows that β-catenin adapts to fit the bulky NR by a distributed conformational change, with bending residues found in ARM-6 and ARM-7 ( Fig. S1 , Table S2 ). In contrast, LRH-1 utilizes a region of the LBD surface not previously implicated in protein-protein interactions to contact β-catenin. This region is comprised of predominantly polar residues presented by helices H1, H9, H10, and the loop connecting H9 and H10. This surface is distinct from the LRH-1 AF-2, which contacts SRCs and NR0B family corepressors such as Dax-1 and SHP, and lies on the opposite side of the LBD from the H7-H11 region implicated in contacts with one of the two Dax-1 subunits in the LRH-1/ðDax-1Þ 2 heterotrimeric complex (25) .
The observed binding mode may edit assemblies of LRH-1. Part of the LRH-1/β-catenin binding surface overlaps a segment of the LBD (H10 with its preceding loop) that mediates dimer or heterodimer contacts in other NRs, including thyroid hormone receptors, retinoic acid receptors, and peroxisome proliferatoractivated receptors (51) (52) (53) . We have proposed that surfaceexposed acidic residues in H10 of LRH-1 and SF-1 result in repulsive interactions that prevent formation of canonical homodimers and retinoid X receptor (RXR)/heterodimers by these receptors (18) and these sequence alterations could also help to create the β-catenin interaction surface described here (18, 54) .
How General Is the Observed Association? The LRH-1/β-catenin structure may provide clues to possible interaction modes of other NRs with β-catenin. It is likely that other NR5A subfamily members share an analogous β-catenin binding surface; LRH-1 residues that interact with β-catenin are highly conserved among different species and are well conserved in the close homolog SF-1 (NR5A1, Fig. S4 ). Previously published reports of mutational studies proposed that helix H1 of SF-1 is needed for the receptor binding to β-catenin (30, 31, 55) . Although our structure confirms that H1 plays a role in β-catenin contacts, the critical binding segment defined in these mutational studies is positioned at the C terminus of H1 and does not contact β-catenin in our structure (31) . However, it is possible that multiple mutations of SF-1 H1 introduce local changes to the protein fold and could diminish β-catenin binding via indirect effects on the receptor fold.
In addition to the NR5A subfamily, correlations between LRH-1 and AR interactions with β-catenin are apparent. ARM-5 and -6 are essential for β-catenin interaction with AR in yeast two-hybrid assays (33) . This region of β-catenin ( Fig. S6B) , colored in blue) constitutes part of its binding interface with LRH-1 (Fig. S2 ). We find that multiple mutations that disrupt LRH-1/β-catenin binding also disrupt AR/β-catenin interactions (Fig. 6) , and that the TCF-4 peptide competes highly efficiently for AR binding to β-catenin. Two additional studies support the idea that AR binds to the same region of β-catenin. First, mutations of K312A (ARM-4) and K386A (ARM-6) in β-catenin were shown to abolish the interaction of β-catenin with liganded AR LBD (56) . Second, p300-dependent acetylation of β-catenin K345 was shown to inhibit AR/β-catenin association (57) , and we verified the importance of this residue for AR interactions with β-catenin in this study (Fig. 6 ). Thus, LRH-1 and AR dock onto a similar β-catenin surface.
There may be analogies between β-catenin docking surface for LRH-1 and AR, the nature of other NR LBD β-catenin binding interfaces remains a mystery. Outside of the NR5A family, we do not observe any significant conservation of amino acids homologous to those contacting β-catenin in the LRH-1/β-catenin structure. Part of the observed LRH-1 surface (H9-H10) contacting β-catenin will be in competition with homo-or heterodimer interactions in most NRs. For AR and other steroid hormone receptors, which do not form RXR-type LBD-LBD dimers, this region might be occluded by the extended F domain at the C terminus of H12 (58) . This suggests that NRs that are not obligate monomers or contain an F-domain extension must either contain unique β-catenin interaction surfaces that differ from the one seen in LRH-1 or that other NRs rearrange to bind to β-catenin. The structure of β-catenin might be flexible enough to accommodate binding of various protein partners by adjusting its conformation ( Fig. S1, Table S2 ). Ultimately, the nature of β-catenin interactions with other NR will require further investigation.
Implications for LRH-1 and Wnt/β-Catenin Signaling. Botrugno et al. suggested that LRH-1 can interact with β-catenin in two ways (27) . In the first, LRH-1 recruits β-catenin as a classic coactivator. In the second, it is independent of direct LRH-1/DNA contacts; LRH-1 interacts with a TCF-4/β-catenin complex, potentiating its activity. Our data, however, suggest that simultaneous association of LRH-1 and TCF-4 with β-catenin in the manner observed in respective X-ray structures with the two factors is sterically impossible. Indeed, overexpression of TCF-4 inhibits β-catenin coactivation of NR (59) supporting the notion that NR and TCF-4 might compete for binding to β-catenin. How then could LRH-1 enhance cyclin D1 expression by acting as a coactivator of the TCF-4/β-catenin complex? One possibility is that LRH-1 utilizes a distinct β-catenin contact surface to form the proposed assembly. We favor another model, in which LRH-1 might displace one of the two TCF-4 α-helices contacting β-catenin for the two proteins to interact jointly with β-catenin. Clearly, this mechanism will require further investigation.
Finally, the structure suggests interesting mechanisms for assembly of multifactor transcription complexes. NR LBDs are known to engage in multiple protein-protein contacts with coregulators (60), and β-catenin is shown to bind many proteins including a wide variety of transcription factors (34) . Because the LRH-1/β-catenin structure reveals a unique protein interaction interface that is distinct from AF-2, the LRH-1 LBD may have the capacity to accept β-catenin along with other interacting partners, nucleating formation of multicomponent transcription complexes. We and others have suggested that it may be possible to develop new compounds that inhibit NR action by binding directly to key protein interaction surfaces. Thus, it is plausible that β-catenin binding site of LRH-1 and other NRs could be a target for drug discovery. Further focused screening efforts are needed to investigate this possibility.
Materials and Methods
A complementary DNA (cDNA) fragment encoding human LRH-1 residues 191-541 corresponding to hLRH-1 LBD with the preceding hinge region and a cDNA fragment encoding human β-catenin residues 138-663 were cloned into pET32 Xa/LIC and pCDF-2 Ek/ligation independent cloning vectors, respectively, with introduced tobacco etch virus protease cleavable sites, coexpressed in BL21Star (DE3) cells (Invitrogen), and purified using Ni-nitrilotriacetate beads (Qiagen). The proteins were further purified with Superdex 200 10∕30 (GE Healthcare), concentrated to 15 mg∕mL, and crystallized in 20 mM Tris·HCl (pH 8.5) and 40% PEG200 at 20°C. The diffraction data was obtained at the Advanced Light Source (Lawerence Berkeley National Laboratory) Beamline (BL) 8.3.1. The space group of the crystal was P2 1 with cell dimensions of a ¼ 49.8 Å, b ¼ 151.6 Å, c ¼ 76.1 Å, and β ¼ 96.96°. The structure was solved by molecular replacement using the program Phaser (61) in Collaborative Computation Project 4 suite (62) using a β-catenin fragment (PDB ID: 2Z6H (40)) and the LRH-1 LBD (PDB ID: 1YOK (19)) structures as the search models. The structure was refined to 2.8 Å with R free ∕R work values of 24.26∕19.88 with programs Coot (63) and Phenix.refine (64) . Details of the materials, methods, and associated references are in the SI Materials and Methods.
